Equibles does not estimate personal net worth.
Get an email with a short summary when Neurocrine Biosciences Inc publishes a filing, an earnings call transcript or a press release.
Get NBIX alertsMatthew C. Abernethy is recorded as CFO at Neurocrine Biosciences Inc (NBIX). The newest filing on record that lists Matthew C. Abernethy as CFO at Neurocrine Biosciences Inc (NBIX) is dated April 15, 2026. The proxy statement of Neurocrine Biosciences Inc reports total compensation of $6,311,912 for Matthew C. Abernethy in fiscal 2025, including a base salary of $725,913. Disclosed compensation is on record for 9 fiscal years. Matthew C. Abernethy has spoken on 2 earnings calls across 1 company, most recently for Neurocrine Biosciences Inc on October 28, 2025. Neurocrine Biosciences Inc is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Neurocrine Biosciences Inc includes Kevin Gorman (CEO and Board Member), Kyle Gano, Ph.D. (CEO and Board Member), Kyle W. Gano (CEO and Board Member) and 7 others.
“The third quarter was strong across the board for Neurocrine, with $790 million in net product sales, reflecting 28% year-over-year growth. Driven by continued progress both from CRENESSITY and INGREZZA, congrats to all involved in the performance of these 2 medicines.”
“Neurocrine's evolution into a multiproduct growth company was underscored by $682 million in net product sales during the second quarter, representing 17% year-over-year growth.”
Start not stated–present
Last confirmed April 15, 2026
Drug Manufacturers - Specialty & Generic · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Neurocrine Biosciences Inc (NBIX) | Chief Financial Officer | $725,913 | $6,311,912 |
| 2024 | Neurocrine Biosciences Inc (NBIX) | Chief Financial Officer | $684,824 | $6,595,201 |
| 2023 | Neurocrine Biosciences Inc (NBIX) | Chief Financial Officer | $646,061 | $6,057,882 |
| 2022 | Neurocrine Biosciences Inc (NBIX) | Chief Financial Officer | $618,240 | $4,924,323 |
| 2021 | Neurocrine Biosciences Inc (NBIX) | Chief Financial Officer | $588,800 | $5,906,850 |
| 2020 | Neurocrine Biosciences Inc (NBIX) | Chief Financial Officer | $545,200 | $6,281,176 |
| 2019 | Neurocrine Biosciences Inc (NBIX) | Chief Financial Officer | $495,600 | $5,823,120 |
| 2018 | Neurocrine Biosciences Inc (NBIX) | Chief Financial Officer | $420,000 | $2,685,747 |
| 2017 | Neurocrine Biosciences Inc (NBIX) | Chief Financial Officer | $38,231 | $3,789,292 |
